Cyclopentyl-1-cyclopentylamin | 61423-28-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Cyclopentyl-1-cyclopentylamin
• 英文别名: [1,1'-Bi(cyclopentane)]-1-amine；1-cyclopentylcyclopentan-1-amine
• CAS: 61423-28-7
• 化学式: C₁₀H₁₉N
• 分子量: 153.268
• InChiKey: UQMZFXVYWHPBOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-Cyclopentyl-6-azabicyclo<3.1.0>hexan 在 镍 氢氧化钾 、 氢气 作用下， 以 乙醇 为溶剂， 生成 Cyclopentyl-1-cyclopentylamin
  参考文献：
  名称：

  Ricart,G.; Couturier,D., Bulletin de la Societe Chimique de France, 1976, p. 569 - 576

  摘要：

  DOI：

文献信息

• [EN] ANTIFUNGAL COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ANTIFONGIQUES ET PROCÉDÉS S'Y RAPPORTANT
  申请人：KALYRA PHARMACEUTICALS INC

  公开号：WO2017100171A1

  公开（公告）日：2017-06-15

  Compounds of the Formula (I) and (II) as described herein, or pharmaceutically acceptable salts thereof, are described, along with pharmaceutical compositions comprising such compounds, salts or combinations thereof, and methods for making them. Such compounds, salts and compositions are useful for inhibiting fungal growth. For example, in an embodiment, fungal infections can be treated by administering effective amounts of such compounds, salts and/or compositions to a subject in need thereof.

  本文描述的式(I)和(II)的化合物，或其药学上可接受的盐，以及包含这些化合物、盐或其组合的药物组成物被描述，还描述了制备它们的方法。这些化合物、盐和组成物对抑制真菌生长有用。例如，在一种实施方式中，可以通过向需要治疗的受试者施用这些化合物、盐和/或组成物的有效量来治疗真菌感染。
• [EN] 1-(3-(6-(3-HYDROXYNAPHTHALEN-1-YL)BENZOFURAN-2-YL)AZETIDIN-1YL)PROP-2-EN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS KRAS G12C MODULATORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 1-(3-(6-(3-HYDROXYNAPHTALEN-1-YL)BENZOFURAN-2-YL)AZÉTIDIN-1YL)PROP-2-EN-1-ONE ET COMPOSÉS SIMILAIRES UTILISÉS EN TANT QUE MODULATEURS DE KRAS G12C POUR LE TRAITEMENT DU CANCER
  申请人：ARAXES PHARMA LLC

  公开号：WO2018140513A1

  公开（公告）日：2018-08-02

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, isotopic form or stereoisomer thereof, wherein A is a five-membered heteroaryl comprising 1 or 2 non-adjacent heteroatoms, inclusive of X and Y; W, X, Y, Z, L, L1, E, R1, R2b R2c and the dotted circle are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and compounds for use in methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided. Preferred compounds are e.g. l-(3-(6-(3-hydroxynaphthalen-l- yl)benzofuran-2-yl)azetidin-lyl)prop-2-en-l-one derivatives and related compounds such as e.g. the corresponding derivatives with e.g. a benzoimidazole, indole, benzooxazole, imidazopyridine or imidazole core structure, substituted on ring A by e.g. azetidine, pyrrolidine, azepane or bicyclopentane-amine (L1) each substituted by e.g. propenone (E), and the core structure substituted on the six-membered ring with e.g. 3-hydroxynaphthalene or indazole or hydroxy-, alkoxy- and/or fluoro-substituted phenyl (R1).

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。这些化合物具有以下结构（I）：或其药学上可接受的盐、同位素形式或立体异构体，其中A是一个包含1个或2个非相邻杂原子（包括X和Y）的五元杂芳基；W、X、Y、Z、L、L1、E、R1、R2b、R2c和虚线圆圈的定义如本文所述。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物和用于调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法中使用的化合物。优选的化合物例如是l-(3-(6-(3-羟基萘-1-基)苯并呋喃-2-基)氮杂环丙烷-1-基)丙-2-烯-1-酮衍生物和相关化合物，例如相应的具有苯并咪唑、吲哚、苯并噁唑、咪唑吡啶或咪唑核心结构的衍生物，环A上被例如氮杂环丙烷、吡咯烷、氮杂庚烷或双环戊烷胺（L1）取代，每个取代基例如是丙酮（E），并且核心结构在六元环上被例如3-羟基萘或吲唑或羟基、烷氧基和/或氟取代苯基（R1）取代。
• 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
  申请人：Araxes Pharma LLC

  公开号：US11279689B2

  公开（公告）日：2022-03-22

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, isotopic form or stereoisomer thereof, wherein A is a five-membered heteroaryl comprising 1 or 2 non-adjacent heteroatoms, inclusive of X and Y; W, X, Y, Z, L, L1, E, R1, R2b R2c and the dotted circle are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and compounds for use in methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided. Preferred compounds are e.g. 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and related compounds such as e.g. the corresponding derivatives with e.g. a benzoimidazole, indole, benzooxazole, imidazopyridine or imidazole core structure, substituted on ring A by e.g. azetidine, pyrrolidine, azepane or bicyclopentane-amine (L1) each substituted by e.g. propenone (E), and the core structure substituted on the six-membered ring with e.g. 3-hydroxynaphthalene or indazole or hydroxy-, alkoxy- and/or fluoro-substituted phenyl (R1).

  提供了具有作为 G12C 突变 KRAS 蛋白抑制剂活性的化合物。这些化合物具有以下结构(I)：或其药学上可接受的盐、同位素形式或立体异构体，其中A是包含1或2个非相邻杂原子的五元杂芳基，包括X和Y；W、X、Y、Z、L、L1、E、R1、R2b R2c和虚圈如本文所定义。本发明还提供了与制备和使用此类化合物相关的方法、包含此类化合物的药物组合物以及用于调节G12C突变型KRAS蛋白活性以治疗疾病（如癌症）的化合物。优选化合物如 1-(3-(6-(3-羟基萘-1-基)苯并呋喃-2-基)氮杂环丁烷-1-基)丙-2-烯-1-酮衍生物及相关化合物，如具有苯并咪唑、吲哚、苯并恶唑、咪唑吡啶或咪唑等核心结构，在环 A 上被氮杂环丁烷、吡咯烷酮等取代的相应衍生物。例如，氮杂环丁烷、吡咯烷、氮杂环庚烷或双环戊烷胺（L1），各自被丙 酮（E）取代，核心结构在六元环上被 3-羟基萘或吲唑或羟基、烷氧基和/或氟代苯基 （R1）取代。
• POSITIV ALLOSTERISCHE MODULATOREN DES MUSKARINERGEN M2 REZEPTORS
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3307741A1

  公开（公告）日：2018-04-18
• POSITIONING APPARATUS AND GRIPPING APPARATUS
  申请人：Howard Hughes Medical Institute

  公开号：US20220401065A1

  公开（公告）日：2022-12-22

  A gripping apparatus includes: a temperature adjusting device held in a substrate wherein the substrate defines an open region; a phase change material held within the open region and thermally coupled with the temperature adjusting device such that a temperature change in the temperature adjusting device causes a temperature change in the phase change material; and a controller connected to the temperature adjusting device and configured to send a signal to the temperature adjusting device to change its temperature and thereby change the temperature of the phase change material that is thermally coupled with the temperature adjusting device. The phase change material is either in a solid state and configured to grip a stick or in a liquid state and the phase change material and configured to loosen its grip on the stick such that the stick is capable of moving through the phase change material.